Group 1: Earnings Season Overview - The 2025 Q1 earnings season is concluding, with most S&P 500 companies having reported results, which have been generally positive despite uncertainty from tariff discussions [1][19] Group 2: Netflix Performance - Netflix (NFLX) has seen a significant stock surge of 90% over the past year, attributed to strong results and reaffirmation of FY25 guidance [3][19] - Subscriber growth has been a key highlight, with only one quarter of negative growth in the last 12 quarters, and the introduction of ad-supported tiers has been successful [4][5] - The crackdown on password sharing has resulted in increased revenue opportunities, contributing to consistent double-digit percentage year-over-year sales growth for six consecutive periods [5] Group 3: Eaton Performance - Eaton (ETN) reported record Q1 adjusted EPS of $2.72 (up 13% YoY), record Q1 sales of $6.4 billion (up 7% YoY), and record segment margins of 23.9% (80 basis points increase YoY) [8] - Organic sales growth reached 9%, exceeding previous guidance, and backlog growth in the Electrical segment improved by 6% YoY, while Aerospace backlog surged by 16% [9] - The company has demonstrated a commitment to shareholder returns, with a 7% five-year annualized dividend growth rate [11] Group 4: Centene Performance - Centene (CNC) reported adjusted EPS of $2.90 and sales of $46.6 billion, exceeding consensus estimates with earnings up 28% YoY [13] - The company raised its 2025 premium and service revenues guidance by $6.0 billion due to higher-than-expected membership growth, reflecting a 17% YoY increase [13] - Analysts have adjusted sales expectations, with Centene now projected to achieve $179.6 billion in revenues for the current fiscal year [17]

Core Insights - Centene Corporation (CNC) benefits from a growing Medicaid membership, an aging U.S. population, contract wins, strategic acquisitions, and a strong financial position [1] Financial Performance - Centene currently holds a Zacks Rank 2 (Buy) and has seen its stock gain 7.3% over the past three months, contrasting with a 22.1% decline in the industry [2] - The Zacks Consensus Estimate for Centene's 2025 earnings is $7.27 per share, reflecting a year-over-year improvement of 1.5%, with revenues estimated at $179.6 billion, indicating a 10.2% increase [5] - The 2026 earnings estimate is $7.69 per share, showing a 5.7% increase from 2025, with revenues projected at $180 billion, a slight growth of 0.2% [5] - Centene's average earnings surprise over the last four quarters is 25.47%, with three out of four quarters exceeding estimates [7] Valuation Metrics - Centene's price-to-earnings (P/E) ratio stands at 11.17, compared to the multiline industry’s trailing 12-month P/E of 7.95, indicating that the stock is currently undervalued [8] Growth Drivers - Revenue growth is driven by an expanding Medicaid member base, which reached 27.9 million as of March 31, 2025, contributing to premium growth [9] - Premium and service revenues increased by 17% year-over-year in Q1 2025, with management projecting revenues between $164 billion and $166 billion for 2025, representing a 13.4% growth from 2024 [11] - Centene has secured Medicaid contract awards in Nevada, Arizona, and Illinois, and its Commercial Marketplace division serves 5.6 million members, a 29.4% year-over-year increase [11] Strategic Initiatives - The company actively engages in mergers and acquisitions to enhance capabilities and geographic reach while divesting non-core assets to focus on Managed Care operations [12] - Centene's financial stability is supported by a strong liquidity position, holding $14.8 billion in cash and cash equivalents as of March 31, 2025, a 5.3% increase from the end of 2024 [13]

Core Concept - The article emphasizes the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with potential for exceptional returns, alongside more commonly used ratios like price-to-earnings (P/E) and price-to-sales (P/S) [1][5]. P/B Ratio Overview - The P/B ratio is calculated by dividing the market price per share by the book value of equity per share, indicating how much investors are willing to pay for a share relative to its book value [1][5]. - A P/B ratio of less than one suggests that a stock is undervalued, while a ratio greater than one indicates it may be overvalued [5][6]. Book Value Definition - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [3][4]. Limitations of P/B Ratio - The P/B ratio is particularly useful for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenses or significant debt [8][9]. Screening Parameters for Investment - Stocks with a P/B ratio lower than the industry median are considered to have potential for price appreciation [10]. - Additional screening criteria include lower P/S and P/E ratios compared to industry medians, a PEG ratio of less than 1, a current price of at least $5, and a minimum average trading volume of 100,000 [11][12][13]. Identified Low P/B Stocks - Centene Corporation (CNC) is highlighted as a diversified healthcare company with a projected 3-5 year EPS growth rate of 11.5% and a Zacks Rank of 2 [14][15]. - CVS Health (CVS) is noted for its integrated pharmacy care services, with a projected EPS growth rate of 11.4% and a Zacks Rank of 2 [15]. - Pfizer (PFE), a major pharmaceutical company, has a projected EPS growth rate of 9.0% and a Zacks Rank of 2 [16]. - StoneCo (STNE), a financial technology provider, boasts a high projected EPS growth rate of 26.3% and a Zacks Rank of 1 [17]. - Banco Santander (SAN), the largest bank in Spain, has a projected EPS growth rate of 8.6% and a Zacks Rank of 2 [18].

Market Overview - Wall Street experienced a strong rally, with the S&P 500 rising 3.3% to 5,844.19, the Nasdaq Composite climbing 4.4% to 18,708.34, and the Dow Jones Industrial Average gaining 2.8% to 42,410.10, driven by optimism over U.S.-China trade relations [1][2]. Trade Relations - A 90-day agreement between the U.S. and China to reduce tariffs has been established, with the U.S. lowering duties on Chinese imports from 145% to 30%, and China cutting retaliatory tariffs on American goods from 125% to 10, indicating a shift towards cooperation [1]. Value Investing Strategy - The current market conditions may present an opportunity to focus on value stocks, particularly those with strong fundamentals that have been undervalued due to external factors [2][4]. - The Price to Cash Flow (P/CF) ratio is highlighted as an effective metric for evaluating value stocks, with lower ratios indicating better financial health [3][6]. Valuation Metrics - Various valuation metrics are essential for assessing a company's financial position, with P/CF being a key indicator due to its reliability in reflecting a company's cash generation capabilities [5][7]. - Positive cash flow is crucial for a company's liquidity, enabling it to manage debt, reinvest, and return value to shareholders, while negative cash flow can hinder these capabilities [8]. Stock Selection Criteria - To identify true-value stocks, parameters such as P/CF, price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio should be considered, along with a favorable Zacks Rank and Value Score [9][10][11][12][13]. - Specific stocks that meet these criteria include StoneCo Ltd. (STNE), Centene Corporation (CNC), CVS Health Corporation (CVS), and Pfizer Inc. (PFE), each with varying growth estimates and performance metrics [14][15][16].

Industry Overview - The healthcare industry has faced challenges in early 2025, including concerns over potential cuts to Medicare and Medicaid, as well as the impact of tariffs on supplies [1] - Despite these challenges, healthcare stocks have performed relatively well, with the Health Care Select Sector SPDR Fund (XLV) down less than 2% year-to-date, compared to the S&P 500's decline of nearly 3% [1] Company Analysis: Centene - Centene Corp. (CNC) has shown solid membership and revenue growth, primarily driven by its Medicaid services, which have helped it withstand market volatility [3][4] - For Q1 2025, Centene reported a 29% year-over-year increase in Marketplace membership and a 22% increase in Medicare membership, contributing to a 28% improvement in adjusted diluted earnings per share (EPS) and a 17% growth in premium and service revenue [4] - The company has reiterated its full-year guidance, indicating optimism for future performance [4] Company Analysis: Tenet Healthcare - Tenet Healthcare Corp. (THC) has received positive analyst ratings, with 13 Buy ratings and four Holds, following a strong Q1 2025 earnings report that exceeded EPS estimates by $1.25 per share, reflecting a year-over-year improvement of over 35% [6][7] - The company plans to invest $250 million annually in its Ambulatory segment and has opened six new centers in Q1 2025, which are expected to drive continued growth [8] - Tenet's share repurchase program and efforts to improve its balance sheet are anticipated to enhance shareholder value [8] Company Analysis: Encompass Health - Encompass Health Corp. (EHC) reported better-than-expected earnings, leading to increased price targets from analysts [10] - The company's shares have risen over 25% year-to-date, with expectations of 10% projected earnings growth in the near term [11]

Centene (CNC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Core Insights - Oklahoma Complete Health is enhancing its SoonerSelect benefits to improve health outcomes and overall well-being for its members [1][2] Benefit Enhancements - Introduction of a $30 per month Diaper Club for members aged 0-1 whose parents are enrolled in the Start Smart for Your Baby program or care management, starting July 1 [2] - Expansion of prescription limits where certain essential medicines will not count towards the 6-prescription monthly limit, aiding members who require more medications [3] - Over-the-Counter benefits will now provide a $30 allowance per member per quarter, allowing members to purchase items like cold medicines and vitamins [4] - Transportation benefits have been upgraded to allow up to 4 family members to accompany members to doctor's appointments, along with providing up to 15 rides for other essential trips [5] Member Engagement and Impact - In its first year, Oklahoma Complete Health completed over 11,651 referrals for social drivers of health needs, assisted more than 2,500 members with Food Rx benefits, facilitated over 20,684 YMCA visits, and distributed more than $2.1 million in reward dollars for healthy activities [6] - Member testimonials highlight the positive impact of the services provided, emphasizing support in accessing resources and maintaining communication [7] Organizational Overview - Oklahoma Complete Health is a care management organization focused on serving Oklahomans with various health insurance solutions and is a subsidiary of Centene Corporation [8][9]

Valuation Metrics - The price-to-earnings (P/E) ratio is a common valuation metric, but for companies with losses or minimal profits, the price-to-sales (P/S) ratio is more effective in identifying undervalued stocks [1] - The price-to-book (P/B) ratio is another useful tool for identifying low-priced stocks with high growth potential, calculated by dividing the stock's current price by its book value per share [2][6] Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [4][5] - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued, while a ratio above one may indicate overvaluation [6][7] Stock Examples - Centene Corporation (CNC) is a diversified healthcare company with a projected 3-5 year EPS growth rate of 11.5%, currently holding a Zacks Rank of 2 and a Value Score of A [16][17] - Pediatrix Medical Group (MD) provides specialized physician services with a projected EPS growth rate of 9.5% and also holds a Zacks Rank of 2 and a Value Score of A [18][19] - Pfizer (PFE), a major pharmaceutical company, has a projected EPS growth rate of 13.8% and maintains a Zacks Rank of 2 and a Value Score of A [19] - StoneCo (STNE) offers financial technology solutions with a projected EPS growth rate of 26.3%, holding a Zacks Rank of 1 and a Value Score of B [20] - Banco Santander (SAN), the largest bank in Spain, has a projected EPS growth rate of 9.6% and a Zacks Rank of 2 with a Value Score of A [21][22] Screening Parameters - Stocks with a P/B ratio less than the industry median indicate potential for price appreciation [12] - A P/S ratio lower than the industry average makes a stock more attractive [12] - A P/E ratio (F1) below the industry median is considered favorable [13] - A PEG ratio of less than 1 suggests that a stock is undervalued relative to its growth prospects [14] - Stocks should have a minimum trading price of $5 and an average 20-day volume of at least 100,000 for better liquidity [15]

Financial Data and Key Metrics Changes - The company reported first quarter adjusted diluted EPS of $2.90, consistent with previous expectations, and maintained full-year 2025 adjusted EPS expectations of greater than $7.25 [5][24][37] - Premium and service revenue for Q1 reached $42.5 billion, with an increase in full-year revenue guidance to a midpoint of $165 billion, up from $159 billion [26][38] - The adjusted SG&A expense ratio improved to 7.9% from 8.7% year-over-year, reflecting better expense management [35] Business Line Data and Key Metrics Changes - Medicaid membership remained stable at approximately 12.9 to 13 million members, with a Medicaid HBR of approximately 93%, showing slight improvement from 93.4% in Q4 2024 [27][28] - The Medicare segment's HBR was 86.3%, with expectations of an inverted slope due to changes from the Inflation Reduction Act [32] - The commercial segment saw strong growth, with a Q1 HBR of 75.0%, up from 73.3% the previous year, driven by new marketplace members [34] Market Data and Key Metrics Changes - The company noted an increase in flu-related medical expenses of $130 million in Q1, which impacted overall performance but was expected to be a transitory issue [12][28] - The company anticipates a full-year composite Medicaid rating increase of over 4% [30] - The Medicare Advantage membership is projected to contribute an additional $1 billion to revenue guidance for 2025 due to better-than-expected retention [16] Company Strategy and Development Direction - The company is focused on margin recovery and aligning rates with member acuity across various geographies [11] - Strategic initiatives include advocating for sound health care policy and executing on contract wins in Medicaid, such as in Illinois and Nevada [14][15] - The company aims to achieve breakeven in Medicare Advantage by 2027, leveraging STARZ results and operational efficiencies [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the dynamic policy landscape, noting bipartisan support for extending health care premium tax credits [8][9] - The company remains optimistic about long-term growth, citing the attractiveness of end markets and the potential for market share capture [24][25] - Management acknowledged the challenges posed by high-cost drugs and the need for continued focus on operational efficiency [78][120] Other Important Information - The company is preparing for potential changes in the marketplace due to proposed rules from CMS, which could impact market dynamics starting in 2026 [22][42] - The risk corridor mechanism is expected to provide some protection against high specialty drug costs, which are anticipated to increase in 2026 [109][126] Q&A Session Summary Question: Details on flu-related costs and their impact - Management confirmed that the $130 million in flu-related costs was tracked closely and isolated to Medicaid, with no significant impact on Medicare [49][51] Question: Long-term earnings potential - Management reiterated optimism about expanding Medicaid margins and achieving breakeven in Medicare Advantage, with potential for revenue growth [54][56] Question: Impact of public exchange subsidies - Management indicated that the estimate of a $1 impact per share from the loss of enhanced APTCs remains valid, with ongoing discussions about potential extensions [57][61] Question: Risk adjustment and membership growth - Management noted that risk adjustment numbers remained consistent with expectations, and the majority of new membership is subsidized, aligning with the company's focus on low-income populations [96][99] Question: Specialty drug trends - Management highlighted the increasing trend in specialty drug utilization, particularly in non-low-income PDP members, and the need for states to adapt their programs accordingly [118][120]

Core Insights - Centene Corporation (CNC) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.90, exceeding the Zacks Consensus Estimate by 22.9% and reflecting a 28% year-over-year increase [1] - Revenues increased by 15.4% year over year to $46.6 billion, surpassing the consensus mark by 7.2% [1] Revenue Breakdown - Medicaid revenues grew 4% year over year to $22.3 billion, while Medicare revenues surged 48% year over year to $8.8 billion [3] - Commercial revenues improved 31% year over year to $10.1 billion [3] - Total premiums reached $41.7 billion, a 17.4% year-over-year increase, driven by higher premiums and expanding membership in the Prescription Drug Plan (PDP) [4] Service Revenues and Income - Service revenues decreased by 3.8% year over year to $777 million, although it exceeded the consensus mark [5] - Investment and other income fell 29.9% year over year to $382 million, missing the consensus estimate [5] Membership and Health Benefits Ratio - Total membership was 27.9 million as of March 31, 2025, down 1.7% year over year, missing consensus expectations [6] - Membership in the Commercial business increased significantly by 27.3% year over year [6] - The health benefits ratio (HBR) deteriorated by 40 basis points year over year to 87.5% [6] Financial Performance - Adjusted net earnings rose 18.7% year over year to $1.4 billion [7] - Operating expenses totaled $45.1 billion, a 14.7% year-over-year increase, attributed to higher medical costs and administrative expenses [7] - Adjusted SG&A expense ratio improved by 80 basis points year over year to 7.9% [8] Cash and Debt Position - As of March 31, 2025, cash and cash equivalents were $14.8 billion, a 5.3% increase from the end of 2024 [9] - Total assets increased by 5.6% to $87 billion, while long-term debt decreased by 0.6% to $18.3 billion [9] Share Repurchase and Guidance - Centene repurchased common shares worth $41 million in the first quarter, with a remaining capacity of $2.2 billion under its share repurchase authorization [11] - For 2025, management anticipates premium and service revenues between $164-$166 billion, indicating a growth of 13.4% from 2024 [12] - Adjusted EPS is expected to exceed $7.25, reflecting a 1.1% increase from 2024 [13]